Further, ITGB1 has been reported to trigger EGFR ligand-independent proliferation signaling in pancreatic ductal adenocarcinoma, bypassing the EGFR-blocking effect of the anti-EGFR monoclonal antibody Cetuximab 68. Here, EGFR is linked to pancreatic ductal adenocarcinoma.